ما هو علاج ارتفاع ضغط الشريان الرئوي الثانوي لأمراض الرئة؟

References

DOI: 10.1093/eurheartj/ehac237

• The therapeutic approach to group 3 PH starts with optimizing the treatment of the underlying lung disease, including supplementary oxygen and non-invasive ventilation, where indicated, as well as enrolment into pulmonary rehabilitation programmes.
• In patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where indicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation.
• It is recommended to refer eligible patients with lung disease and PH for LTx evaluation.
• The use of PAH medication is not recommended in patients with lung disease and non-severe PH.